bremelanotide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
The research was taken up by Wilhelm Kühne, who named the pigment rhodopsin, also known as "visual purple." Kühne confirmed that rhodopsin is extremely sensitive to light, and thus enables vision in low-light conditions, and that it was this chemical decomposition that stimulated nerve impulses to the brain. Research stalled until after identification of "fat-soluble vitamin A" as a dietary substance found in milkfat but not lard, would reverse night blindness and xerophthalmia. In 1925, Fridericia and Holm demonstrated that vitamin A deficient rats were unable to regenerate rhodopsin after being moved from a light to a dark room.
The Napoleonic Wars (1803–1815) were a global series of conflicts fought by a fluctuating array of European coalitions against the French First Republic (1803–1804) under the First Consul followed by the First French Empire (1804–1815) under the Emperor of the French, Napoleon. The wars originated in political forces arising from the French Revolution (1789–1799) and French Revolutionary Wars (1792–1802) and produced a period of French domination over continental Europe. The wars are categorised as seven conflicts, five named after the coalitions that fought Napoleon, plus two named for their respective theatres: the War of the Third Coalition, War of the Fourth Coalition, War of the Fifth Coalition, War of the Sixth Coalition, War of the Seventh Coalition, the Peninsular War, and the French invasion of Russia. The first stage of the wars broke out when Britain declared war on France on 18 May 1803. After minor campaigns, Britain allied with Austria, Russia, and minor powers, to form the Third Coalition in April 1805. Napoleon defeated the allied Russo-Austrian armies in the subsequent war which climaxed in French victories at Ulm and at Austerlitz, leading to the dissolution of the Holy Roman Empire and Austria being forced to make peace. Britain and Russia remained at war with France. Concerned about increasing French power, Prussia joined Britain and Russia in the Fourth Coalition, which resumed war in October 1806.
Ciguatera fish poisoning (CFP), also known as ciguatera, is a foodborne illness caused by eating tropical reef fish contaminated with ciguatoxins. Such individual fish are said to be ciguatoxic. Symptoms may include diarrhea, vomiting, numbness, itchiness, dysesthesia, sensitivity to hot and cold, dizziness, and weakness with lethargy. The onset of symptoms varies with the amount of toxin absorbed. If a large quantity of toxins is consumed, symptoms may appear within half an hour. At lower amounts, symptoms may take a few days to appear. Diarrhea may last up to four days. Symptoms may last a few weeks to a few months. Heart problems such as slow heart rate and low blood pressure may occur. Shoemaker, House, and Ryan published a case definition of a chronic form of ciguatera poisoning that may develop: "Roughly 5% of these victims will develop chronic ciguatera (CC), a widespread, multisymptom, multisystem, chronic illness that can last tens of years." The specific toxins involved are ciguatoxins and maitotoxin. They are made by a small marine organism, Gambierdiscus toxicus, that grows on and around coral reefs in tropical and subtropical waters. These are eaten by herbivorous fish which in turn are eaten by larger carnivorous fish. The toxins become more concentrated as they move up the food chain. The fish most often implicated include barracuda, grouper, moray eel, amberjack, and sea bass. Diagnosis is based on a person's symptoms together with having recently eaten fish. If a number of those who eat the same fish develop symptoms the diagnosis becomes more likely.
pseudomallei in 99% of cases, as does the automated Vitek 1 system, but the automated Vitek 2 system only identifies 19% of isolates. The pattern of resistance to antimicrobials is distinctive, and helps to differentiate the organism from P. aeruginosa. The majority of B. pseudomallei isolates are intrinsically resistant to all aminoglycosides (via an efflux pump mechanism), but sensitive to co-amoxiclav: this pattern of resistance almost never occurs in P. aeruginosa and is helpful in identification. Unfortunately, the majority of strains in Sarawak, Borneo, are susceptible to aminoglycosides and macrolides, which means the conventional recommendations for isolation and identification do not apply there. Molecular methods (PCR) of diagnosis are possible, but not routinely available for clinical diagnosis. Fluorescence in situ hybridisation has also been described, but has not been clinically validated, and it is not commercially available. In Thailand, a latex agglutination assay is widely used, while a rapid immunofluorescence technique is also available in a small number of centres.
== Horse racing scandals == Show jumping horse killings – from 1975 to 1995, wealthy owners and trainers of show jumping horses conspired to electrocute and otherwise kill over-valued as well as under-performing animals in a 20-year-long scheme to defraud insurance companies. Crimes also committed during this equestrian sports scandal include extortion, mail fraud, animal cruelty and the murder of at least one human being. Fine Cotton/Bold Personality ring-in – a 1984 betting scam in which the conspirators, which included some elite figures in Australian Thoroughbred racing, substituted the far more talented Bold Personality for Fine Cotton in a low-class race. The scheme was discovered immediately after the race and the investigation led to lifetime bans for six individuals and bans of more than a decade for at least two more. 2020 Horse racing doping scam – the scam was revealed in March 2020, when the FBI cracked down several top names in American horse racing. Initially, 27 people (trainers and veterinarians) were charged with doping, which later increased to 29 people.
Sources: en.wikipedia.org
==== Fugitive, new sentences, and marriage ==== Olofsson escaped from the Norrköping prison on 20 March 1975. In April that year, he went into a bank in Copenhagen with a gun in each hand, fired a warning shot, and robbed the bank of SEK194,000. One month after the escape, Olofsson was in Marseille on the French Riviera. Together with a companion, he bought the sailboat Saga for 50,000 francs, and for three months they sailed around the Mediterranean. In August, they passed through the Strait of Gibraltar, out onto the Atlantic past the Azores. With the help of Inger and Mikael von Heijne from Djursholm, on their way home from the Caribbean, Olofsson got on the right course and finally reached Ireland. From there, they went to Denmark where Danish police came upon them. Olofsson escaped and it was not until January 1976 that the police caught up with him and managed to track him down at a crossroads outside Brussels. He managed to shoot himself free; on a train in Germany during this escape, he met 19-year-old Marijke Demuynck. On 24 March 1976, Olofsson robbed Handelsbanken on Östra Hamngatan 27 in Gothenburg of SEK 930,000 - at the time the largest robbery in Swedish criminal history. At the same time, he took two people hostage. He was arrested at 22:30, nine hours after the robbery, at hotel Gyllene Kärven in Herrljunga. SEK 230,000 was recovered during Olofsson‘s arrest; the rest was never found.
== Production == Ammonium acetate is produced by the neutralization of acetic acid with ammonium carbonate or by saturating glacial acetic acid with ammonia. Obtaining crystalline ammonium acetate is difficult on account of its hygroscopic nature.
=== Environmental monitoring === Autonomous data loggers can be taken to diverse locations that cannot easily support fixed temperature monitoring equipment. These might include: mountains, deserts, jungles, mines, ice flows, caves, etc. Portable data loggers are also used in industry and laboratory situations where stand-alone recording is desired.
=== Acquisition of ZLB Bioplasma AG and Aventis Behring === In 2000, CSL doubled its size through the purchase of a Swiss plasma company, the Bern-based ZLB Bioplasma AG. In 2004, during a period of plasma oversupply, the company expanded again with the purchase of the German medical company Aventis Behring. The company was the second Australian public company to have reached a share price of over $100 per share.
Sources: en.wikipedia.org
== Early life == Simco was born on January 29, 1982, in Houston, Texas, to Anita Isaacs, a maid, and Ronald Simco, a Vietnam War veteran with severe post-traumatic stress disorder, who worked various jobs, including as a police officer and Walmart manager. His mother grew up in Shaker Heights, Ohio, descending from a family of German Jews and Lithuanian Jews that included several survivors and victims of the Holocaust. Riff Raff is the second of four siblings. He and his family lived in Copperfield, a suburb 25 miles northwest of Houston. Growing up he was obsessed with basketball, playing frequently with other children in his neighborhood. The Simcos had moved to nearby Stone Creek. He attended Langham Creek High School, where he was shooting guard on his school's basketball team, before dropping out in his senior year. Shortly thereafter he obtained his GED. After his parents divorced, his father was diagnosed with tonsil cancer and the family moved to Duluth, Minnesota, to get his father out of the heat into a cooler environment. For a time, Riff Raff and his siblings were shuttled back and forth between Duluth and Houston, where their mother remained. In 2001, he enrolled at Hibbing Community College in Hibbing, Minnesota, where he played on the basketball team for a month and majored in liberal arts. Feeling out of place, he dropped out in 2003 and moved back to Houston, where he painted cars in the in-vogue "candy-colored" style and gradually built his new identity. He eventually relocated to Los Angeles and began to take his rapping career seriously.
=== Aversion therapy === Aversion therapy in alcoholism had its roots in Russia in the early 1930s, with early papers by Pavlov, Galant and Sluchevsky and Friken, and would remain a strain in the Soviet treatment of alcoholism well into the 1980s. In the US a particularly notable devotee was Dr Voegtlin, who attempted aversion therapy using apomorphine in the mid to late 1930s. However, he found apomorphine less able to induce negative feelings in his subjects than the stronger and more unpleasant emetic emetine.
== Structure == The Gβγ subunit is a dimer composed of two polypeptides, however it acts functionally as a monomer, as the individual subunits do not separate, and have not been found to function independently. The Gβ subunit is a member of the β-propeller family of proteins, which typically possess four to eight antiparallel β-sheets arranged in the shape of a propeller. Gβ contains a seven-bladed β-propeller, each blade arranged around a central axis and composed of four antiparallel β-sheets. The amino acid sequence contains seven WD repeat motifs of about 40 amino acids, each highly conserved and possessing the Trp-Asp dipeptide that gives the repeat its name. The Gγ subunit is considerably smaller than Gβ, and is unstable on its own, requiring interaction with Gβ to fold, explaining the close association of the dimer. In the Gβγ dimer, the Gγ subunit wraps around the outside of Gβ, interacting through hydrophobic associations, and exhibits no tertiary interactions with itself. The N terminus helical domains of the two subunits form a coiled coil with one another that typically extends away from the core of the dimer. To date, five β-subunit and eleven γ-subunit genes have been identified in mammals. The Gβ genes have very similar sequences, while significantly greater variation is seen in the Gγ genes, indicating that the functional specificity of the Gβγ dimer may be dependent on the type of Gγ subunit involved.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.